Estrogen_NN
binding_NN
sites_NNS
in_IN
peripheral_JJ
blood_NN
monocytes_NNS
and_CC
effects_NNS
of_IN
danazol_NN
on_IN
their_PRP$
sites_NNS
in_FW
vitro_FW
._.

1_LS
._.
This_DT
study_NN
was_VBD
designed_VBN
to_TO
investigate_VB
the_DT
presence_NN
of_IN
estrogen_NN
type_NN
I_NN
-LRB-_-LRB-
high_JJ
affinity_NN
,_,
low_JJ
capacity_NN
-RRB-_-RRB-
and_CC
type_NN
II_CD
-LRB-_-LRB-
low_JJ
affinity_NN
,_,
high_JJ
capacity_NN
-RRB-_-RRB-
binding_VBG
sites_NNS
in_IN
human_JJ
peripheral_JJ
blood_NN
monocytes_NNS
and_CC
the_DT
effects_NNS
of_IN
danazol_NN
on_IN
these_DT
sites_NNS
._.

2_LS
._.
These_DT
two_CD
types_NNS
of_IN
estrogen_NN
binding_NN
sites_NNS
existed_VBD
in_IN
human_JJ
peripheral_JJ
blood_NN
monocytes_NNS
._.

3_LS
._.
Danazol_NN
bound_VBD
to_TO
these_DT
sites_NNS
in_IN
high_JJ
concentration_NN
-LRB-_-LRB-
10_CD
-LRB-_-LRB-
-6_CD
-RRB-_-RRB-
M_NN
,_,
clinical_JJ
serum_NN
concentration_NN
during_IN
danazol_NN
therapy_NN
-RRB-_-RRB-
and_CC
decreased_VBD
the_DT
number_NN
of_IN
both_DT
sites_NNS
._.

4_LS
._.
It_PRP
is_VBZ
suggested_VBN
that_IN
danazol_NN
has_VBZ
an_DT
anti-estrogenic_JJ
action_NN
to_TO
the_DT
monocytes_NNS
through_IN
the_DT
competition_NN
and_CC
suppression_NN
of_IN
estrogen_NN
binding_NN
sites_NNS
as_IN
seen_VBN
in_IN
the_DT
estrogen_NN
target_NN
organ_NN
._.

